The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.

Disclosed herein are methods of labeling organic compounds without depending on any functional group of the compound. In some embodiments, provided are bifunctional linkers useful in the methods.

Disclosed is a compound of formula (I):

##STR00001## wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

Compounds that can be used to increase NAD levels are described by inhibiting NAD+ degrading enzymes such as CD38 are described. The compounds have a structure according to formula I or Formula II, as described herein, or pharmaceutically acceptable salts thereof, wherein the attached groups are as defined in the specification. Methods of increasing intracellular NAD+ levels in a subject by administering an effective amount of a compound according to formula I or formula II to the subject are also described.

Compounds that can be used to increase NAD levels are described by inhibiting NAD+ degrading enzymes such as CD38 are described. The compounds have a structure according to formula I or Formula II, as described herein, or pharmaceutically acceptable salts thereof, wherein the attached groups are as defined in the specification. Methods of increasing intracellular NAD+ levels in a subject by administering an effective amount of a compound according to formula I or formula II to the subject are also described.

Disclosed herein are methods for inducing insulin secretion in a glucose-dependent manner and compounds for use in these methods.

Disclosed herein are methods for inducing insulin secretion in a glucose-dependent manner and compounds for use in these methods.

The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.

Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).